These results indicate that the HER2-CD3-Fc mRNA-LNPs can be directly used in place of the HER2-CD3-Fc bsAb to induce T cell cytotoxicity against HER2-positive tumor cells. The gene discussed is ERBB2; the disease is neoplasm.